Article
Oncology
Zeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, Sumedha Sudhaman, Turkan Ozturk Topcu, Matt Nichols, Justin Martin, Katherine M. M. Bui, Charuta C. C. Palsuledesai, Meenakshi Malhotra, Perry Olshan, Joseph Markowitz, Nikhil I. I. Khushalani, Ahmad A. A. Tarhini, Jane L. L. Messina, Alexey Aleshin
Summary: In this study, a personalized and tumor-informed ctDNA assay was used to analyze plasma samples from 69 patients with advanced melanoma. The results showed that ctDNA levels were correlated with survival and disease progression in these patients, suggesting that it could be a reliable biomarker for predicting treatment response and disease recurrence.
Review
Oncology
Helena J. Janse van Rensburg, Pavlina Spiliopoulou, Lillian L. Siu
Summary: Circulating biomarkers play a valuable role in evaluating disease states in solid malignancies, and their use in monitoring treatment response is diverse, including disease burden markers, tumor markers, circulating tumor cells, nucleic acids, exosomes, and metabolomic arrays. This review summarizes the discovery and application of these circulating biomarkers in influencing treatment decisions, as well as the barriers to their application.
Review
Oncology
Estela Sanchez-Herrero, Roberto Serna-Blasco, Lucia Robado de Lope, Victor Gonzalez-Rumayor, Atocha Romero, Mariano Provencio
Summary: This article provides an overview of the biological features of circulating tumor DNA (ctDNA), including size, structure, shedding and clearance mechanisms, as well as the pathological factors that determine ctDNA levels. A better understanding of ctDNA biology is crucial for the development of new methods for ctDNA analysis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Genetics & Heredity
Meng Zhang, Changsong Qi, Zhenghang Wang, Hui Chen, Xiaochen Zhao, Xueming Zhang, Yifan Zhou, Chan Gao, Yuezong Bai, Shuqin Jia, Jiafu Ji
Summary: This study of 200 Chinese patients with advanced gastric adenocarcinoma revealed that the majority carried genomic alterations, with common mutations in genes like TP53, LRP1B, MYC, ERBB2, and KRAS. Patients with high bTMB and bMSI-H had a higher percentage of del-alterations in the DDR pathway. Over 45% of cases had potentially actionable alterations, showing promise for ctDNA NGS in informing clinical decisions for advanced gastric adenocarcinoma.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2021)
Letter
Oncology
Parmida Sadat Pezeshki, Reza Ghalehtaki
Summary: Colorectal cancer is a major cause of cancer-related deaths globally. A significant portion of patients present with rectal cancer in the locally-advanced stage, requiring multi-modality therapy. Utilizing circulating tumor DNA for predicting response to neoadjuvant therapy shows promise in improving patient selection for non-surgical approaches.
BIOMARKER RESEARCH
(2023)
Article
Oncology
Andrea Gombos, David Venet, Lieveke Ameye, Peter Vuylsteke, Patrick Neven, Vincent Richard, Francois P. Duhoux, Jean-Francois Laes, Francoise Rothe, Christos Sotiriou, Marianne Paesmans, Ahmad Awada, Thomas Guiot, Patrick Flamen, Martine Piccart-Gebhart, Michail Ignatiadis, Geraldine Gebhart
Summary: Biomarkers such as F-18-FDG-PET/CT non-response and ctDNA detection can help identify patients with metastatic breast cancer who may not benefit from adding everolimus to endocrine treatment. Patients who show metabolic non-response or detect ctDNA after 14 days of treatment have a lower probability of benefiting from the treatment, as indicated by shorter progression-free survival. Validation from independent studies is necessary.
Review
Oncology
Wenyu Chen, Haijiao Yan, Xiaodong Li, Kele Ge, Jun Wu
Summary: ctDNA, a fragmented genomic material, serves as a crucial biomarker in tumor diagnosis and monitoring. Its non-invasive nature makes it a preferred choice for patients with limited sample collection. Gastric cancer, a malignancy influenced by multiple factors, presents challenges for researchers focusing on genetic and epigenetic changes.
TRANSLATIONAL CANCER RESEARCH
(2021)
Article
Oncology
Anja E. Eisenhardt, Zacharias Brugger, Ute Lausch, Jurij Kiefer, Johannes Zeller, Alexander Runkel, Adrian Schmid, Peter Bronsert, Julius Wehrle, Andreas Leithner, Bernadette Liegl-Atzwanger, Riccardo E. Giunta, Steffen U. Eisenhardt, David Braig
Summary: This study utilized a highly sensitive targeted next-generation sequencing approach to monitor tumor dynamics in synovial sarcoma patients. The detection of circulating tumor DNA (ctDNA) correlated with the presence of viable tumor tissue, allowing for non-invasive detection of tumor recurrence and monitoring of treatment response. The findings suggest that targeted NGS could be a valuable tool for the diagnosis and treatment of synovial sarcoma.
Review
Chemistry, Analytical
Fatemeh Farshchi, Mohammad Hasanzadeh
Summary: This article summarizes the recent developments and innovations in biosensors for the detection of circulating tumor DNA (ctDNA). Various biosensing platforms, including electrochemical, optical, and nanotechnology-based sensors, have been surveyed for ctDNA detection. The article discusses the design, fabrication, and analytical performance of these biosensors, as well as their potential applications in clinical analysis. Additionally, the challenges and future prospects of ctDNA biosensors are also discussed, highlighting the potential for continued development and refinement of these devices for improved early cancer diagnosis and prognosis.
MICROCHEMICAL JOURNAL
(2023)
Article
Oncology
Katherine Clifton, Jingqin Luo, Yu Tao, Jennifer Saam, Thereasa Rich, Anna Roshal, Ashley Frith, Caron Rigden, Foluso Ademuyiwa, Katherine Weilbaecher, Leonel Hernandez-Aya, Lindsay L. Peterson, Nusayba Bagegni, Rama Suresh, Ron Bose, Mateusz Opyrchal, Tanya M. Wildes, Cynthia Ma
Summary: This study aimed to assess mutation profiles in older adult breast cancer patients using a ctDNA assay, and found more frequent ATM, BRAF, and PIK3CA mutations in older patients. Results also showed that ctDNA testing influenced treatment management in a portion of patients from a single institution.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Lisa S. M. Hofste, Maartje J. Geerlings, Daniel von Rhein, Sofie H. Tolmeijer, Marjan M. Weiss, Christian Gilissen, Tom Hofste, Linda M. Garms, Marcel J. R. Janssen, Heidi Rutten, Camiel Rosman, Rachel S. van der Post, Bastiaan R. Klarenbeek, Marjolijn J. L. Ligtenberg
Summary: Ultradeep sequencing-based detection of circulating tumor DNA in preoperative plasma of patients with locally advanced esophageal cancer can predict which patients have a high risk of recurrence after neoadjuvant chemoradiotherapy and surgery.
Article
Oncology
Abbas Karimi, Tohid Jafari-Koshki, Mojtaba Zehtabi, Farzaneh Kargar, Tarik Gheit
Summary: Liquid biopsy using HPV ctDNA can predict the rate of relapse or recurrence after treatment, with post-treatment measurement being more effective than baseline assessment. HPV ctDNA could be used as a surrogate or incorporated with other methods for detecting residual disease.
Article
Oncology
Vincent K. Lam, Jianjun Zhang, Carol C. Wu, Hai T. Tran, Lerong Li, Lixia Diao, Jing Wang, Waree Rinsurongkawong, Victoria M. Raymond, Richard B. Lanman, Jeff Lewis, Emily B. Roarty, Jack Roth, Stephen Swisher, J. Jack Lee, Don L. Gibbons, Vassiliki A. Papadimitrakopoulou, John Heymach
Summary: The study found a moderate but significant correlation between ctDNA variant allele frequency and imaging measures of tumor burden, with varying strengths based on tumor genotypes. Factors such as TP53 and EGFR mutations, visceral metastasis, and tumor burden were independent predictors of increased ctDNA shedding, suggesting that ctDNA levels are affected by both tumor burden and genotype.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Panagiotis Filis, Ioannis Kyrochristos, Efterpi Korakaki, Evangelos G. Baltagiannis, Dimitris Thanos, Dimitrios H. Roukos
Summary: Biomarkers are used to guide targeted therapy in metastatic disease, while ctDNA MRD detection is used to guide adjuvant treatment in the nonmetastatic setting.
DRUG DISCOVERY TODAY
(2023)
Article
Oncology
Shenglin Ma, Meiqi Shi, Xueqin Chen, Yong Wang, Zhenhua Yang, Analyn Lizaso, Min Li, Haiyan Li, Lu Zhang, Xinru Mao, Xingxiang Xu, Yong Song
Summary: This study demonstrated that molecular factors derived from serial ctDNA profiling can serve as predictive and prognostic markers, allowing early detection of PD preceding imaging modalities by 2.5 months.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Immunology
Yu Chen, Yingying Huang, Xuan Gao, Yi Li, Jing Lin, Lizhu Chen, Lianpeng Chang, Gang Chen, Yanfang Guan, Leong Kin Pan, Xuefeng Xia, Zengqing Guo, Jianji Pan, Yaping Xu, Xin Yi, Chuanben Chen
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Oncology
Wencheng Zhang, Cihui Yan, Xuan Gao, Xiaoxia Li, Fuliang Cao, Gang Zhao, Jingjing Zhao, Puchun Er, Tian Zhang, Xi Chen, Yuwen Wang, Yao Jiang, Quanren Wang, Baozhong Zhang, Dong Qian, Jun Wang, Dejun Zhou, Xiubao Ren, Zhentao Yu, Lujun Zhao, Zhiyong Yuan, Ping Wang, Qingsong Pang
Summary: The study showed that radiotherapy plus anti-PD-1 antibody as first-line therapy for locally advanced esophageal squamous cell carcinoma is safe and feasible, with tumor-infiltrating and peripheral lymphocytes being associated with patient survival, suggesting potential for further exploration as a treatment option.
Article
Genetics & Heredity
Jian Zhao, Xiaoxiong Xiao, Yue Li, Xuan Gao, Xiuqin Zhang, Zeyi Liu, Yuting Yi, Xiaorui Fu, Han Wang, Yanfang Guan, Xuefeng Xia, Weixing Zhang, Jian'an Huang
Summary: HLA-I LOH prevalence varies across different cancer types, and is associated with genomic instability and higher tumor mutation burden levels. Enrichment of alterations in DNA damage response pathways and higher mutation rates of tumor suppressors are seen in HLA-I LOH cases. These findings may have implications for future tumor immunology research.
Review
Immunology
Gang Xiao, Zhiyuan Liu, Xuan Gao, Han Wang, Haiqin Peng, Jiahui Li, Lei Yang, Hexin Duan, Rongrong Zhou
Summary: Brain metastases are common in NSCLC patients and immune checkpoint inhibitors (ICIs) have become a routine treatment for these patients. Various ICIs have been approved for the first-line treatment of metastatic NSCLC, but the use of PD-L1, tumor infiltrating lymphocytes, and tumor mutation burden as predictive biomarkers for ICIs in NSCLC patients with BM remains controversial with insufficient clinical data.
Article
Oncology
Bing Liu, Yaqi Wang, Han Wang, Zhongwu Li, Lujing Yang, Shi Yan, Xin Yang, Yuanyuan Ma, Xuan Gao, Yanfang Guan, Xin Yi, Xuefeng Xia, Jingjing Li, Nan Wu
Summary: The study demonstrates that RBM10 deficiency enhances anti-tumor immunity in lung adenocarcinoma, with higher HLA expression and immune cell infiltration, along with increased expression of certain immune checkpoint molecules.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Gang Xiao, Xuan Gao, Lifeng Li, Chao Liu, Zhiyuan Liu, Haiqin Peng, Xuefeng Xia, Xin Yi, Rongrong Zhou
Summary: A six-gene immune-related prognostic signature was developed for IDH-mutant LGGs, showing promising independent prognostic value and potential to enhance individualized therapy and clinical outcomes. The study also refined the classification system of IDH-mutant gliomas, stratifying patients into subtypes with distinct immunophenotypes and overall survival.
JOURNAL OF ONCOLOGY
(2021)
Article
Immunology
Feng Wang, Xuan Gao, Peiyuan Wang, Hao He, Peng Chen, Zhentian Liu, Yujie Chen, Hang Zhou, Weijie Chen, Xin Yi, Xuefeng Xia, Shuoyan Liu
Summary: In LUAD patients, the C3 inflammatory immune subtype is the most common and accurate prognostic subtype. It is associated with longer survival and has higher levels of immune cells and gene pathway expression, as well as lower levels of tumor-associated cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jie Dai, Xue Bai, Xuan Gao, Lirui Tang, Yu Chen, Linzi Sun, Xiaoting Wei, Caili Li, Zhonghui Qi, Yan Kong, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Zelong Xu, Bin Lian, Siming Li, Xieqiao Yan, Bixia Tang, Li Zhou, Xuan Wang, Xuefeng Xia, Jun Guo, Lili Mao, Lu Si
Summary: In this study, the response and survival of patients with primary malignant melanoma of the esophagus (PMME) and non-esophageal mucosal melanoma (NEMM) under anti-PD-1 monotherapy were analyzed. PMME showed a better response to anti-PD-1 treatment compared to NEMM, with higher objective response rate and disease control rate. Genomic and transcriptome analyses revealed molecular differences between PMME and NEMM, supporting the distinct molecular characteristics of PMME.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Gang Xiao, Lifeng Li, Guilong Tanzhu, Zhiyuan Liu, Xuan Gao, Xin Wan, Desheng Xiao, Liu Chen, Xuefeng Xia, Rongrong Zhou
Summary: This study found that lung adenocarcinomas (LUAD) with EGFR-positive and ALK-positive had a suppressive tumor immune microenvironment (TIME) and were less responsive to immunotherapy. The TIME in patients with EGFR/ALK-positive LUAD brain metastases (BMs) was different from that in primary lung cancer. Evaluating the immune characteristics of LUAD BMs is important for clinical treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
